Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate

Annals of Clinical Biochemistry

Volumn 33, Issue 3, 1996, Pages 187-189

  Malik, K J ^a   Wakelin, K ^a   Dean, S ^a   Cove, D H ^a   Wood, P J ^a,b  

^a Weymouth and District Hospital   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carcinoma of the breast

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KIDNEY CARCINOMA; PRIORITY JOURNAL;

EID: 0029948654     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329603300302     Document Type: Article

References (14)

1. Siminoski K, Goss P, Drucker D. The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med 1989; 111: 758-60
2. Donckier JE, Michel LA, Buysschaert M. Cushing syndrome and medroxyprogesterone acetate. Lancet 1990; 335: 1094
3. Grenfell A, Rudenski A, Watts M, Wiltshire C, Day JL, Gray IP. Cushing's syndrome and medroxyprogesterone acetate. Lancet 1990; ii: 256
4. Merrin P, Alexander WD. Cushing's induced by medroxyprogesterone. BMJ 1990; 301: 345
5. Glenn EM, Richardson SL, Bowman BJ. Biologic activity of 6 alpha-methyl compounds corresponding to progesterone, 17 alpha hydroxyprogesterone acetate and Compound S. Metabolism 1959; 8: 265-85
6. Guthrie GP, John WJ. The in vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate. Endocrinology 1980; 107: 1393-6
7. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor: correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983; 32: 1511-18
8. Lundblad JR, Roberts J. Regulation of proopiomelanocortin gene expression in pituitary. Endocrine Rev 1989; 9: 135-58
9. Camanni F, Massara F, Molinatti GM. The cortisone-like effect of 6α-methyl-17α-acetoxy progesterone in the adrenalactomized man. Acta Endocrinol 1963; 43: 477-83
10. Matthews JH, Abrams CAL, Morishima A. Pituitary-adrenal function in ten patients receiving medroxyprogesterone acetate for true precocious puberty. J Clin Endocrinol Metab 1970; 30: 653-8
11. Sadoff L, Lusk W. The effect of large doses of medroxyprogesterone acetate (MPA) on urinary oestrogen levels and serum levels of cortisol T4, LH and testosterone in patients with advanced cancer. Obstet Gynecol 1973; 43: 262-7
12. Hellman L, Yoshida K, Zumoff B, Levin J, Klean J, Fukushima D. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976; 42: 912-16
13. Leis D, Botterman P, Ermler R, Henderkott H, Gluck H. The influence of high doses of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH. Arch Gynecol 1980; 230: 9-13
14. Pannuti F, Fonet F, Piaha E. The anabolic effect induced by high doses of medroxyprogesterone acetate (MPA) orally in cancer patients. IRCS Med Sci 1978; 6: 118